<DOC>
	<DOCNO>NCT01480050</DOCNO>
	<brief_summary>RATIONALE : Mibefradil dihydrochloride may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I trial study best dose mibefradil dihydrochloride give together temozolomide treat patient glioma .</brief_summary>
	<brief_title>Mibefradil Dihydrochloride Temozolomide Treating Patients With Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum-tolerated dose ( MTD ) mibefradil dihydrochloride administer prior five day temozolomide ( TMZ ) 150-200 mg/m² subject progressive recurrent high-grade glioma . Secondary - Assess safety mibefradil dihydrochloride administer prior five day TMZ 150-200 mg/m² mibefradil dihydrochloride dose escalate start dose 100 mg/day , give four time day seven consecutive day . - Determine pharmacokinetic profile mibefradil . - Determine steady state level mibefradil dihydrochloride last day dose . - Assess severity frequency adverse event test mibefradil dihydrochloride dose level include cumulative toxicity and/or tolerance adverse effect . - Estimate number type radiographic response treatment mibefradil dihydrochloride temozolomide . - Assess potential effect mibefradil dihydrochloride tumor metabolism determine Fluorothymidine Positron Emission Tomography ( FLT PET ) scan radiotracer [ 18F ] -3'-fluoro-3'-deoxy-L-thymidine ( dose-expansion cohort ) . OUTLINE : This dose-escalation study mibefradil dihydrochloride follow dose-expansion study . Patients receive mibefradil dihydrochloride orally ( PO ) 4 time day day 1-7 ( day 1-8 first course ) temozolomide PO day 8-12 ( day 9-13 first course ) . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Blood sample collect first course pharmacokinetic study . Patients dose-expansion cohort undergo [ 18F ] -3'-fluoro-3'-deoxy-L-thymidine ( FLT ) -positron emission tomography ( PET ) baseline day 7 first course therapy . After completion study therapy , patient follow every 2 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Mibefradil</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven highgrade glioma ( glioblastoma , anaplastic astrocytoma , anaplastic oligodendroglioma , mixed anaplastic oligoastrocytoma , anaplastic ependymoma ) progressive recurrent follow standard upfront radiation therapy + temozolomide Measurable contrastenhancing progressive recurrent highgrade glioma ( single multiple lesion ) MRI image within 30 day start treatment Must plan retreatment temozolomide 150200 mg/m² 5 day per cycle ; cycle = 28 day Must previously tolerate least one cycle adjuvant temozolomide therapy prior treatment glioma PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 60 % Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500/µL Platelets ≥ 100,000/µL Total bilirubin &lt; equal 3 time institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; equal 3 time ULN Creatinine normal OR creatinine clearance ≥ 50 mL/min Serum potassium , magnesium , calcium level normal ( may correct level supplementation screen period ) Not pregnant nursing Negative pregnancy test Women childbearing potential men must agree use adequate contraception Able tolerate MRIs CT scan substitute MRIs study No concurrent malignancy except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix , breast , bladder Subjects prior malignancy must diseasefree ≥ five year MiniMental State Exam score ≥ 15 Patients must identify caregiver/support person agree assist remote cardiac monitor taking/recording blood pressure home No serious concurrent infection medical illness , would jeopardize ability subject receive treatment outline protocol reasonable safety No uncontrolled intercurrent illness include , limited , hypertension , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement No history know , active hepatitis No screening QTc interval ≥ 450 mSec male 470 mSec females No PR interval &gt; 250 mSec No systolic blood pressure &lt; equal 100 mm Hg baseline No history ( within six month ) myocardial infarction , unstable angina , uncontrolled hypertension , congestive heart failure No highgrade ( second degree ) AV block persistent sinus bradycardia le 50 BPM No known HIVpositivity PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered CTCAE grade &lt; equal 2 toxicity relate prior therapy An interval least 3 month must elapse since completion recent course radiation therapy , last dose temozolomide ( TMZ ) , placement Gliadel wafers No prior cytotoxic therapy temozolomide Gliadel wafer Prior antiVEGF therapy allow four month elapse end prior treatment 30 day must elapse since previous treatment brain tumor agent Must maintain stable decrease corticosteroid regimen ( increase 7 day ) prior start treatment Patients may receive investigational agent chemotherapeutic agent temozolomide No antiarrhythmia medication betablockers digoxin No requirement calcium channel blocker blood pressure control switch antihypertensive alternative mechanism action Permitted antihypertensive medication include : chlorothiazide , hydrochlorothiazide , atenolol , nadolol , enalapril , lisinopril , eprosartan , irbesartan Patients receive statin trial except pravastatin No treatment H2 blocker , famotidine If patient require proton pump inhibitor ( PPI ) , esomeprazole , pantoprazole , rabeprazole may give No concurrent enzymeinducing antiepileptic drug ( EIAEDs ) Patients previously treat EIAEDs may enrol EIAED 10 day prior first dose mibefradil Patients take anticoagulant must use warfarin low molecular weight heparin Unfractionated heparin permit No drug substrates CYP3A4 , CYP2D6 , CYP1A2 except one explicitly permit No drug potential interfere metabolism excretion mibefradil Patients take discontinue overthecounter ( OTC ) medication nutritional supplement , include herbal `` Chinese '' medication , eligible , except follow : OTC medication allow labeled dos dose mibefradil acetaminophen , aspirin , diphenhydramine , calcium carbonate antacid , brand multiple vitamin supplement pseudoephedrine Topical preparation decongestant nasal spray allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>